{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:40:45Z","timestamp":1791348045378,"version":"4.3.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.esmoop.2022.100383","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T13:07:17Z","timestamp":1643116037000},"page":"100383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The good physician and the great physician: why a physician should consider the ESMO guidelines on the management of cancer cachexia?"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Laviano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2022.100383_bib1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamaoncol.2021.5668","article-title":"Progress against cancer mortality 50 years after passage of the National Cancer Act","volume":"8","author":"Kratzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib2","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.esmoop.2022.100383_bib3","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jamaoncol.2021.3600","article-title":"Has the current oncology value paradigm forgotten patients' time? Too little of a good thing","volume":"7","author":"Fundytus","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib4","doi-asserted-by":"crossref","first-page":"e2033004","DOI":"10.1001\/jamanetworkopen.2020.33004","article-title":"Assessment of Food and Drug administration- and European Medicines Agency-approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review","volume":"4","author":"Arciero","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2022.100383_bib5","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1200\/JOP.19.00328","article-title":"Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma","volume":"16","author":"Bange","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2022.100383_bib6","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jamaoncol.2019.3105","article-title":"Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration","volume":"5","author":"Sullivan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1017\/S0029665118000459","article-title":"Nutrition support and clinical outcome in advanced cancer patients","volume":"77","author":"Laviano","year":"2018","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.esmoop.2022.100383_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/jcsm.12525","article-title":"Nutrition interventions to treat low muscle mass in cancer","volume":"11","author":"Prado","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.esmoop.2022.100383_bib10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.annonc.2021.05.793","article-title":"Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial","volume":"32","author":"Bargetzi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib11","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100383_bib12","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jamaoncol.2021.1160","article-title":"Applying a life course biological age framework to improving the care of individuals with adult cancers: review and research recommendations","volume":"7","author":"Mandelblatt","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2022.100383_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jcsm.12875","article-title":"Twelve-year sarcopenia trajectories in older adults: results from a population-based study","volume":"13","author":"Trevisan","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.esmoop.2022.100383_bib14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3945\/ajcn.113.060228","article-title":"Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential?","volume":"98","author":"Prado","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.esmoop.2022.100383_bib15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international Cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100383_bib16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","article-title":"Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers","volume":"7","author":"Parikh","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:25:10Z","timestamp":1761855910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2059702922000035"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100383","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The good physician and the great physician: why a physician should consider the ESMO guidelines on the management of cancer cachexia?","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100383"}}